Abstract
Background Papua New Guinea (PNG) has the highest malaria transmission outside of Africa and long-lasting insecticidal nets (LLINs) are the only vector-control tool distributed country-wide. LLINs were introduced into PNG in about 2006 and have been attributed to have had a huge impact on malaria transmission, with reductions in observed average malaria prevalence from 15.7% (2008) to 1% (2014). However, since 2015 malaria indicators in PNG have risen significantly. Similar trends have been observed in several African nations. In the present study, we observed a drastic reduction in bioefficacy of LLINs collected both from households as used nets and prior to use in original, unopened packaging. We hypothesise that decreased bioefficacy of LLIN is a major contributor to the observed malaria resurgence in PNG and possibly in other parts of the world.
Methods New LLINs in original and unopened packaging (n=192) manufactured between 2007-2019 were collected in 15 PNG provinces. Used LLIN (n=40) manufactured between 2008 and 2017 were collected in 2 provinces. LLIN were subjected to standard WHO cone bioassays using fully susceptible An. farauti mosquitoes. A subset of LLIN was re-tested using fully susceptible An. gambiae G3 mosquitoes in order to ensure reproducibility of results.
Results Only 7% (95% CI 4-12%) of new LLINs manufactured between 2013-2019 exhibited 100% mortality. However, 84% (95%CI: 65-84%) new nets manufactured in 2012 or before exhibited 100% mortality. Only 29 % of used LLIN less than 3 years old exhibited > 80% 24h-mortality. Results obtained in tests using An. farauti corresponded well with confirmatory tests conducted using An. gambiae.
Discussion Bioefficacy of LLIN in PNG appears to have been highly variable since 2013, with few nets manufactured since 2013 meeting WHO standards. This time-frame coincides with malaria resurgence in the country. These results may have ramifications for LLIN-based malaria control that go beyond the local PNG scenario.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded in part by the Global Fund To Fight Aids, Malaria and Tuberculosis; SK and LR are recipients of Australian NHMRC Career Development Fellowships. LT is funded by a JCU PhD Scholarship.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made available as supporting information file (Excel format)
